

Meredith P. Grant
 Email: MPGrant@duanemorris.com
DUANE MORRIS LLP
 750 B Street, Suite 2900
 San Diego, CA 92101-4681
 Tel.: +1 619 744 2235
 Fax: +1 619 393 0246

*Counsel for Defendants Princeton Pharmaceutical Inc.,
 Solco Healthcare U.S., LLC, and Huahai U.S., Inc.*

UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF CALIFORNIA

JOHN JUDSON AND JO ANN HAMEL,
 individually and on behalf of a class of similarly
 situated individuals,

Plaintiffs,

v.

PRINSTON PHARMACEUTICAL INC.; SOLCO
 HEALTHCARE U.S., LLC; HUAHAI U.S., INC.;
 TEVA PHARMACEUTICAL INDUSTRIES, LTD.;
 and, TEVA PHARMACEUTICALS USA, INC.

Defendants.

Case No.: 1:18-cv-01405-DAD-EPG

**STIPULATION AND ORDER TO
 STAY CASE AND DEFER ALL
 DEADLINES PENDING MOTION
 TO TRANSFER ACTIONS TO THE
 DISTRICT OF NEW JERSEY
 PURSUANT TO 28 U.S.C. § 1407 FOR
 COORDINATED OR
 CONSOLIDATED PRETRIAL
 PROCEEDINGS**

Plaintiffs, John Judson and Jo Ann Hamel, and Defendants, Princeton Pharmaceutical Inc. (“Prinston”), Solco Healthcare U.S., LLC (“Solco”), Huahai U.S., Inc. (“Huahai”), and Teva Pharmaceuticals USA, Inc. (“Teva”) (collectively, “Defendants”),¹ by and through their undersigned counsel, hereby stipulate and request that this Court stay all deadlines in this case pending a ruling by the Judicial Panel on Multidistrict Litigation (“JPML”) on Plaintiff Robert Kruk’s Motion to Transfer Actions to the District of New Jersey Pursuant to 28 U.S.C. § 1407 in *In re: Valsartan N-Nitrosodimethylamine (NDMA) Prods. Liab. Litig.*, MDL No. 2875 (J.P.M.L. Oct. 22, 2018):

¹ To the best of Defendants’ knowledge, Teva Pharmaceutical Industries Ltd. has not been served and does not participate in this Stipulation.

1 1. Plaintiff's Complaint was filed on October 11, 2018.

2 2. This case is one of at least eighteen putative federal class action lawsuits involving
3 the medication Valsartan.

4 3. On October 22, 2018, Plaintiff in *Kruk v. Zhejiang Huahai Pharmaceutical Co., Ltd.,*
5 *et al.*, No. 18-cv-005944 (N.D. Ill.) filed in the JPML a Motion to Transfer Actions to the District of
6 New Jersey Pursuant to 28 U.S.C. § 1407 for Coordinated or Consolidated Pretrial Proceedings. *See*
7 *In re: Valsartan N-Nitrosodimethylamine (NDMA) Prods. Liab. Litig.*, MDL No. 2875 (J.P.M.L. Oct. 22,
8 2018) (the "Motion to Transfer," attached as Exhibit A).²

9 4. Plaintiff in the *Kruk* action seeks an order from the JPML transferring NDMA-related
10 Valsartan litigation to the District of New Jersey, including this case, and consolidating those cases
11 or coordinating their pretrial proceedings pursuant to § 1407(a).

12 5. In the interest of judicial economy, and to avoid the risk of inconsistent pretrial
13 rulings, duplicative discovery obligations, inconsistent or overlapping class certification rulings, and
14 to promote the just and efficient conduct of this litigation, the Parties wish to stay this case pending a
15 ruling from the JPML on the Motion to Transfer.

16 6. The JPML is scheduled to hold a hearing on the Motion to Transfer on January 31,
17 2019.³ As such, a stay pending the JPML's ruling would be limited, would last for a brief, definite
18 period, and will not result in undue prejudice to any of the Parties.

19 7. Plaintiffs and all served Defendants consent to this request, and no party will be
20 prejudiced by a stay of the case.

21 NOW, THEREFORE, Plaintiff and Defendants, through their attorneys of record, request
22 this Court stay this case and defer all deadlines. A proposed order is attached to this Motion.

23 **IT IS SO STIPULATED**

24
25 Dated: January 30, 2019

Respectfully submitted,

26 ² This Court has also received notice of the Motion to Transfer. *See* ECF No. 7.

27 ³ *See* Notice of Hearing Session, Exhibit B.
28

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

DUANE MORRIS LLP

/s/ Meredith Grant
Meredith Grant

*Counsel for Defendants Princeton
Pharmaceutical Inc., Solco Healthcare
U.S., LLC, and Huahai U.S., Inc.*

Dated: January 30, 2019

GREENBERG TRAURIG, LLP

/s/ Richard Tabura
Richard Tabura

*Counsel for Defendant Teva
Pharmaceuticals USA, Inc.*

Dated: January 30, 2019

SLACK DAVIS SANGER, LLP

/s/ John R. Davis
John R. Davis

*Counsel for Plaintiffs and Proposed
Class*

Dated: January 30, 2019

KANNER & WHITELY, LLC

/s/ Allan Kanner
Allan Kanner

*Counsel for Plaintiffs and Proposed
Class*

ORDER

This matter having come before the Court on the stipulation of Plaintiffs, John Judson and Jo Ann Hamel, and Defendants, Princeton Pharmaceutical Inc., Solco Healthcare U.S., LLC, Huahai U.S., Inc., and Teva Pharmaceuticals USA, Inc. IT IS HEREBY ORDERED:

1. The stipulated request is granted;
2. All deadlines are VACATED until further order of Court;
3. This action is STAYED pending the ruling by the Judicial Panel on Multidistrict Litigation on the Motion to Transfer Actions to the District of New Jersey Pursuant to 28 U.S.C. § 1407 in *In re: Valsartan N-Nitrosodimethylamine (NDMA) Prods. Liab. Litig.*, MDL No. 2875 (J.P.M.L. Oct. 22, 2018); and
4. The Parties shall file a status report within seven days of the JPML's ruling, apprising the Court of the JPML's decision.

IT IS SO ORDERED.

Dated: **January 31, 2019**

/s/ Eric P. Grogan
UNITED STATES MAGISTRATE JUDGE